Enhancing Therapeutic Outcomes with Smart Drug Carriers

The faster rate in the advancement of drug delivery technology has transformed the practice of modern medicine with greater bioavailability, therapeutic effect, and patient compliance. Low solubility, high clearance, and non-targeted delivery have contributed extensively to conventional drug delivery modes. While overcoming these shortcomings, new drug delivery carriers like liposomes, nanoparticles, and polymer systems are at the forefront as delivery carriers of controlled and targeted therapy.The article addresses the promise, innovation in stimulus-sensitive and ligand-targeted platforms, and translation to industry and clinic for nanoparticle and liposomal drug delivery. Follow-on more recent FDA approvals of other nanomedicine therapeutics show promise and efficacy in infectious disease, management of chronic disease, and cancer. Continuing to revolutionize the era of personalized medicine are the advancement in AI-enabled drug design, nature-inspired delivery platforms, and gene therapy-based carriers.While such monumental leaps have already been made, safety, scale-up, and regulatory challenges must be overcome first before such treatments become the norm around the world. With the synergy of disruptive technologies and best-practice formulation approaches, second-generation drug delivery systems have a generation-defining task to revolutionize therapeutics with more efficient, safer, and patient-more-friendly therapeutics.